Global Small Interfering RNA (siRNA) Therapeutics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Small Interfering RNA (siRNA) Therapeutics market size will reach US$ million by 2031.
Small interfering RNA (siRNA) is a form of genetic medicine that can silence or knock out any overexpressed genes in disease.It"s also called short interfering RNA.These rnas are widely used to assess the specific contributions of genes to a variety of cell phenotypes, including apoptosis, pancreatic bird signaling, cytokinesis, and cell differentiation.They are used to identify novel pathways and have a meaningful impact on the identification of targets for several diseases (such as AIDS, cancer and hepatitis) and cellular processes.The mechanism of action of siRNA involves introducing it into cells.SiRNA sequences should be designed to match the short regions of the target gene.Small interfering rnas are processed by the cell"s own enzymes to eliminate the mRNA of the target gene, thereby preventing overexpression of the pathogenic gene.It is based on the natural response of cells when they detect genetic abnormalities or infections.It has some advantages over the different types of therapies currently available, such as target specificity, reduced secondary effects, and high specificity.The preclinical development duration of small interfering RNA compounds (about 15 to 24 months) is shorter than that of monoclonal antibodies (about 27 to 50 months) or other traditional small molecules (about 42 to 66 months).The shortening of preclinical stage is attributed to the rational design of RNA.The design includes mathematical algorithms assembled in software to select the most appropriate RNA sequence to silence specific genetic targets.They are usually more effective than other traditional medicines.SiRNA therapy includes liposome-based systemic therapy and nanoparticle based systemic therapy.Liposome-based systems are associated with liver-targeted pharmacokinetics, which limits the therapeutic potential of siRNA therapy to other common liver diseases, such as hepatocellular carcinoma, hepatitis, and hypercholesterolemia.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Small Interfering RNA (siRNA) Therapeutics Industry Forecast” looks at past sales and reviews total world Small Interfering RNA (siRNA) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Small Interfering RNA (siRNA) Therapeutics sales for 2025 through 2031. With Small Interfering RNA (siRNA) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Small Interfering RNA (siRNA) Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Small Interfering RNA (siRNA) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Small Interfering RNA (siRNA) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Small Interfering RNA (siRNA) Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Small Interfering RNA (siRNA) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Small Interfering RNA (siRNA) Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Small Interfering RNA (siRNA) Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Liposome Based Systemic Therapy
Nanoparticle Based Systemic Therapy
Other
Segmentation by Application:
Hospital
Research Institutions
Pharmaceutical and Biotechnology Companies
Academic Institutions
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GE
Horizon Discovery
Thermo Scientific
OPKO Health
AInylam Pharmaceuticals
Arrowhead Research
Sanofi Genzyme
Genecon Biotechnologies
Arbutus Biopharma
Silent Therapeutics
Sylentis
Please note: The report will take approximately 2 business days to prepare and deliver.
Small interfering RNA (siRNA) is a form of genetic medicine that can silence or knock out any overexpressed genes in disease.It"s also called short interfering RNA.These rnas are widely used to assess the specific contributions of genes to a variety of cell phenotypes, including apoptosis, pancreatic bird signaling, cytokinesis, and cell differentiation.They are used to identify novel pathways and have a meaningful impact on the identification of targets for several diseases (such as AIDS, cancer and hepatitis) and cellular processes.The mechanism of action of siRNA involves introducing it into cells.SiRNA sequences should be designed to match the short regions of the target gene.Small interfering rnas are processed by the cell"s own enzymes to eliminate the mRNA of the target gene, thereby preventing overexpression of the pathogenic gene.It is based on the natural response of cells when they detect genetic abnormalities or infections.It has some advantages over the different types of therapies currently available, such as target specificity, reduced secondary effects, and high specificity.The preclinical development duration of small interfering RNA compounds (about 15 to 24 months) is shorter than that of monoclonal antibodies (about 27 to 50 months) or other traditional small molecules (about 42 to 66 months).The shortening of preclinical stage is attributed to the rational design of RNA.The design includes mathematical algorithms assembled in software to select the most appropriate RNA sequence to silence specific genetic targets.They are usually more effective than other traditional medicines.SiRNA therapy includes liposome-based systemic therapy and nanoparticle based systemic therapy.Liposome-based systems are associated with liver-targeted pharmacokinetics, which limits the therapeutic potential of siRNA therapy to other common liver diseases, such as hepatocellular carcinoma, hepatitis, and hypercholesterolemia.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Small Interfering RNA (siRNA) Therapeutics Industry Forecast” looks at past sales and reviews total world Small Interfering RNA (siRNA) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Small Interfering RNA (siRNA) Therapeutics sales for 2025 through 2031. With Small Interfering RNA (siRNA) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Small Interfering RNA (siRNA) Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Small Interfering RNA (siRNA) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Small Interfering RNA (siRNA) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Small Interfering RNA (siRNA) Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Small Interfering RNA (siRNA) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Small Interfering RNA (siRNA) Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Small Interfering RNA (siRNA) Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Liposome Based Systemic Therapy
Nanoparticle Based Systemic Therapy
Other
Segmentation by Application:
Hospital
Research Institutions
Pharmaceutical and Biotechnology Companies
Academic Institutions
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GE
Horizon Discovery
Thermo Scientific
OPKO Health
AInylam Pharmaceuticals
Arrowhead Research
Sanofi Genzyme
Genecon Biotechnologies
Arbutus Biopharma
Silent Therapeutics
Sylentis
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
111 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Small Interfering RNA (siRNA) Therapeutics Market Size by Player
- 4 Small Interfering RNA (siRNA) Therapeutics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Small Interfering RNA (siRNA) Therapeutics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
